AstraZeneca-Funded Non-Clinical PhD Studentship: Deciphering cellular determinants of sensitivity to high-LET radiation to inform combination strategies with next-generation Targeted Alpha Therapies

This AstraZeneca-Funded Non-Clinical PhD Studentship covers an index-linked student stipend for 4 years, tuition fees (at Home rate only) and an allocation towards project consumables and training. The successful student will become part of a cohort of Cambridge-AstraZeneca students who will spend time at both institutions over the course of their PhD and come together as a group for training and social events. The student will be working on a collaborative project jointly supervised by Professor Sir Steve Jackson at Cancer Research UK Cambridge Institute and Dr Mark O'Connor at AstraZeneca. The project focuses on deciphering cellular determinants of sensitivity to high-LET radiation to inform combination strategies with next-generation Targeted Alpha Therapies. The position is designed for candidates with excellent laboratory skills and a strong background in biochemistry, molecular biology and genomics. The successful candidate is expected to have excellent communication, organisational and time-management skills, an inquisitive mind, and be highly motivated to drive an independent research project. This studentship offers a unique opportunity to work collaboratively between a world-leading academic cancer research institute and a major pharmaceutical company, with access to cutting-edge facilities and training at both institutions.